BioSpace News Archive

Vir Biotechnology, Inc. (Nasdaq: VIR), a clinical-stage immunology company focused on treating and preventing serious infectious diseases, today announced the closing of its previously announced underwritten public offering of 8,214,285 shares of its common stock at a public offering price of $42.00 per share.

Qualigen Therapeutics, Inc. (NASDAQ: QLGN) (“Qualigen” or the “Company”), today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, with a single institutional investor for the purchase and sale for $8,000,000 of (i) 1,140,570 shares of Common Shares,

Lincoln International is pleased to announce that The Araz Group, Inc. (d/b/a HealthEZ), a leading independent third-party administrator (TPA) of self-funded medical plans, has received an investment from Abry Partners LP, a private investment firm focused on investing in and building market-leading middle market businesses